-
Je něco špatně v tomto záznamu ?
Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study
J. Semenchuk, Y. Naito, SC. Charman, SB. Carr, SY. Cheng, BC. Marshall, A. Faro, A. Elbert, HH. Gutierrez, CH. Goss, B. Karadag, PR. Burgel, C. Colombo, M. Salvatore, R. Padoan, G. Daneau, S. Harutyunyan, N. Kashirskaya, L. Kirwan, PG. Middleton,...
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- COVID-19 * patofyziologie komplikace epidemiologie MeSH
- cystická fibróza * patofyziologie komplikace MeSH
- dospělí MeSH
- index tělesné hmotnosti MeSH
- lidé MeSH
- nutriční stav * MeSH
- respirační funkční testy metody MeSH
- retrospektivní studie MeSH
- SARS-CoV-2 MeSH
- usilovný výdechový objem MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Factors associated with severe COVID-19 infection have been identified; however, the impact of infection on longer-term outcomes is unclear. The objective of this study was to examine the impact of COVID-19 infection on the trajectory of lung function and nutritional status in people with cystic fibrosis (pwCF). METHODS: This is a retrospective global cohort study of pwCF who had confirmed COVID-19 infection diagnosed between January 1, 2020 and December 31, 2021. Forced expiratory volume in one second percent predicted (ppFEV1) and body mass index (BMI) twelve months prior to and following a diagnosis of COVID-19 were recorded. Change in mean ppFEV1 and BMI were compared using a t-test. A linear mixed-effects model was used to estimate change over time and to compare the rate of change before and after infection. RESULTS: A total of 6,500 cases of COVID-19 in pwCF from 33 countries were included for analysis. The mean difference in ppFEV1 pre- and post-infection was 1.4 %, (95 % CI 1.1, 1.7). In those not on modulators, the difference in rate of change pre- and post-infection was 1.34 %, (95 % CI -0.88, 3.56) per year (p = 0.24) and -0.74 % (-1.89, 0.41) per year (p = 0.21) for those on elexacaftor/tezacaftor/ivacaftor. No clinically significant change was noted in BMI or BMI percentile before and after COVID-19 infection. CONCLUSIONS: No clinically meaningful impact on lung function and BMI trajectory in the year following infection with COVID-19 was identified. This work highlights the ability of the global CF community to unify and address critical issues facing pwCF.
Cystic Fibrosis Canada Toronto Canada
Cystic Fibrosis Foundation Bethesda MD USA
Cystic Fibrosis Registry of Ireland Woodview House University College Dublin Ireland
Department of Pediatrics Justus Liebig University Giessen Giessen Germany
Department of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia
Department of Pulmonology University Children`s Hospital Zurich Zurich Switzerland
Department of Respirology St Michael's Hospital Toronto Ontario Canada
Division of Pediatric Pulmonology Marmara University Faculty of Medicine Istanbul Turkey
Dutch CF Foundation Baarn the Netherlands
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico University of Milan Milan Italy
Hospital Clínico Universitario Virgen de la Arrixaca Murcia Spain
Instituto da Criança e do Adolescente HCFMUSP São Paulo Brazil
Italian CF Registry Istituto Superiore di Sanità Rome Italy
Italian Cystic Fibrosis Registry Scientific Board Rome Italy
National Center Rare Diseases Undiagnosed Rare Diseases Interdepartmental Unit
Research Centre for Medical Genetics Moscow Regional Research and Clinical Institute Moscow Russia
UK Trust London United Kingdom
Yerevan University CF Centre Muratsan Hospital Yerevan Armenia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019053
- 003
- CZ-PrNML
- 005
- 20241024111614.0
- 007
- ta
- 008
- 241015s2024 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jcf.2024.07.019 $2 doi
- 035 __
- $a (PubMed)39191560
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Semenchuk, Julie $u Department of Respirology, St. Michael's Hospital, Toronto, Ontario, Canada
- 245 10
- $a Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study / $c J. Semenchuk, Y. Naito, SC. Charman, SB. Carr, SY. Cheng, BC. Marshall, A. Faro, A. Elbert, HH. Gutierrez, CH. Goss, B. Karadag, PR. Burgel, C. Colombo, M. Salvatore, R. Padoan, G. Daneau, S. Harutyunyan, N. Kashirskaya, L. Kirwan, PG. Middleton, R. Ruseckaite, I. de Monestrol, L. Naehrlich, P. Mondejar-Lopez, A. Jung, J. van Rens, E. Bakkeheim, A. Orenti, D. Zomer-van Ommen, LVR. da Silva-Filho, FF. Fernandes, M. Zampoli, AL. Stephenson, Global CF Registry Collaboration
- 520 9_
- $a BACKGROUND: Factors associated with severe COVID-19 infection have been identified; however, the impact of infection on longer-term outcomes is unclear. The objective of this study was to examine the impact of COVID-19 infection on the trajectory of lung function and nutritional status in people with cystic fibrosis (pwCF). METHODS: This is a retrospective global cohort study of pwCF who had confirmed COVID-19 infection diagnosed between January 1, 2020 and December 31, 2021. Forced expiratory volume in one second percent predicted (ppFEV1) and body mass index (BMI) twelve months prior to and following a diagnosis of COVID-19 were recorded. Change in mean ppFEV1 and BMI were compared using a t-test. A linear mixed-effects model was used to estimate change over time and to compare the rate of change before and after infection. RESULTS: A total of 6,500 cases of COVID-19 in pwCF from 33 countries were included for analysis. The mean difference in ppFEV1 pre- and post-infection was 1.4 %, (95 % CI 1.1, 1.7). In those not on modulators, the difference in rate of change pre- and post-infection was 1.34 %, (95 % CI -0.88, 3.56) per year (p = 0.24) and -0.74 % (-1.89, 0.41) per year (p = 0.21) for those on elexacaftor/tezacaftor/ivacaftor. No clinically significant change was noted in BMI or BMI percentile before and after COVID-19 infection. CONCLUSIONS: No clinically meaningful impact on lung function and BMI trajectory in the year following infection with COVID-19 was identified. This work highlights the ability of the global CF community to unify and address critical issues facing pwCF.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a cystická fibróza $x patofyziologie $x komplikace $7 D003550
- 650 12
- $a COVID-19 $x patofyziologie $x komplikace $x epidemiologie $7 D000086382
- 650 12
- $a nutriční stav $7 D009752
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a usilovný výdechový objem $7 D005541
- 650 _2
- $a index tělesné hmotnosti $7 D015992
- 650 _2
- $a SARS-CoV-2 $7 D000086402
- 650 _2
- $a respirační funkční testy $x metody $7 D012129
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Naito, Yumi $u UK Trust, London, United Kingdom
- 700 1_
- $a Charman, Susan C $u UK Trust, London, United Kingdom
- 700 1_
- $a Carr, Siobhán B $u Royal Brompton and Harefield Hospitals, part of Guy's and St Thomas's NHS Foundation Trust and Imperial College, London, United Kingdom
- 700 1_
- $a Cheng, Stephanie Y $u Cystic Fibrosis Canada, Toronto, Canada
- 700 1_
- $a Marshall, Bruce C $u Cystic Fibrosis Foundation, Bethesda, MD, USA
- 700 1_
- $a Faro, Albert $u Cystic Fibrosis Foundation, Bethesda, MD, USA
- 700 1_
- $a Elbert, Alexander $u Cystic Fibrosis Foundation, Bethesda, MD, USA
- 700 1_
- $a Gutierrez, Hector H $u Division of Pediatric Pulmonary and Sleep Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
- 700 1_
- $a Goss, Christopher H $u Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington Medical Center, Seattle, WA, United States
- 700 1_
- $a Karadag, Bulent $u Division of Pediatric Pulmonology, Marmara University Faculty of Medicine, Istanbul, Turkey
- 700 1_
- $a Burgel, Pierre-Régis $u National Reference CF center and Respiratory Medicine, Cochin Hospital APHP and Université Paris Cité, Institut Cochin (InsermU1016), Paris, France
- 700 1_
- $a Colombo, Carla $u Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
- 700 1_
- $a Salvatore, Marco $u National Center Rare Diseases, Undiagnosed Rare Diseases Interdepartmental Unit; Italian CF, Registry, Istituto Superiore di Sanità, Rome, Italy
- 700 1_
- $a Padoan, Rita $u Italian Cystic Fibrosis Registry, Scientific Board, Rome Italy
- 700 1_
- $a Daneau, Géraldine $u Belgian Cystic Fibrosis Registry, Health services research, Department of epidemiology and public health, Sciensano, Belgium
- 700 1_
- $a Harutyunyan, Satenik $u Yerevan University CF Centre, Muratsan Hospital, Yerevan, Armenia
- 700 1_
- $a Kashirskaya, Nataliya $u Research Centre for Medical Genetics, Moscow Regional Research and Clinical Institute ("MONIKI"), Moscow, Russia
- 700 1_
- $a Kirwan, Laura $u Cystic Fibrosis Registry of Ireland, Woodview House, University College Dublin, Ireland
- 700 1_
- $a Middleton, Peter G $u Bronchiectasis and CF service, Department of Respiratory & Sleep Medicine, Westmead Hospital, Sydney, Australia
- 700 1_
- $a Ruseckaite, Rasa $u Department of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
- 700 1_
- $a de Monestrol, Isabelle $u Department of Pediatrics, CLINTEC, Karolinska Institutet, Stockholm CF Center, Karolinska University Hospital Huddinge, Sweden
- 700 1_
- $a Naehrlich, Lutz $u Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany
- 700 1_
- $a Mondejar-Lopez, Pedro $u Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
- 700 1_
- $a Jung, Andreas $u Department of Pulmonology, University Children`s Hospital Zurich, Zurich, Switzerland
- 700 1_
- $a van Rens, Jacqui $u Department of Paediatrics, University Hospital Leuven, Leuven, Belgium, European Cystic Fibrosis Society, Karup, Denmark
- 700 1_
- $a Bakkeheim, Egil $u National Resource Centre for Cystic Fibrosis, Department of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway
- 700 1_
- $a Orenti, Annalisa $u Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, Laboratory of Medical Statistics, Biometry and Epidemiology "G. A. Maccacaro", Università degli Studi di Milano, Milan, Italy
- 700 1_
- $a Zomer-van Ommen, Domenique $u Dutch CF Foundation (NCFS), Baarn, the Netherlands
- 700 1_
- $a da Silva-Filho, Luiz Vicente Rf $u Instituto da Criança e do Adolescente HCFMUSP, São Paulo, Brazil
- 700 1_
- $a Fernandes, Flavia Fonseca $u Medicine Department, Universidade Federal de Catalão, Catalão, Brazil, Hospital de Base do Distrito Federal, Brasília, Brazil
- 700 1_
- $a Zampoli, Marco $u Department of Paediatrics and Child Health, University of Cape Town, Red Cross War Memorial Children's Hospital, Cape Town, South Africa
- 700 1_
- $a Stephenson, Anne L $u Department of Respirology, St. Michael's Hospital, Toronto, Ontario, Canada. Electronic address: Anne.Stephenson@unityhealth.to
- 710 2_
- $a Global CF Registry Collaboration
- 773 0_
- $w MED00006892 $t Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society $x 1873-5010 $g Roč. 23, č. 5 (2024), s. 815-822
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39191560 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111607 $b ABA008
- 999 __
- $a ok $b bmc $g 2201711 $s 1231026
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 23 $c 5 $d 815-822 $e 20240826 $i 1873-5010 $m Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society $n J Cyst Fibros $x MED00006892
- LZP __
- $a Pubmed-20241015
